A species difference in the presystemic metabolism of carbazeran in dog and man
- 1 January 1984
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 14 (12) , 935-945
- https://doi.org/10.3109/00498258409151492
Abstract
1. The bioavailability of carbazeran and the metabolism of carbon-14 labelled drug have been studied in the dog and man following oral administration. 2. The drug was moderately well absorbed in both species, but there was a marked difference in bioavailability and in routes of metabolism. 3. In the dog, systemic bioavailability was approx. 68% and biotransformation involved mainly O-demethylation. 4. In man, bioavaifability was not measurable and carbazeran was almost completely cleared via 4-hydroxylation of the phthalazine moiety. Thus the lack of detectable pharmacological effect in man following oral administration of the drug appears to be due to presystemic metabolism by a particularly active pathway not found in the dog.This publication has 6 references indexed in Scilit:
- Cardiovascular pharmacology: Report of the Main working partyPharmacology & Therapeutics, 1979
- The oxidation of azaheterocycles with mammalian liver aldehyde oxidaseXenobiotica, 1979
- Influence of Route of Administration on Drug AvailabilityJournal of Pharmaceutical Sciences, 1972
- Purification and properties of butyrylcholinesterase from horse serumArchives of Biochemistry and Biophysics, 1971
- Hepatic vascular bed.Physiological Reviews, 1971
- A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomesBiochemical Journal, 1965